Results 111 to 120 of about 36,119 (263)

Cancer Treatment and Bone Health [PDF]

, 2018
Considerable advances in oncology over recent decades have led to improved survival, while raising concerns about long-term consequences of anticancer treatments.
A Falahati-Nini, A Garg, A Lipton, A Llombart, A Morishima, A Tomkinson, AM Brufsky, AR Hong, B Buehring, BF Boyce, BL Clarke, BL Clarke, C Christensen, C Magno, C Poznak Van, C Shapiro, C Wilson, Catherine Handforth, CH Kasperk, CJ Stava, D Goldray, D Vanderschueren, DA Cameron, DA Galvão, DL Hershman, DM Huber, DS Perrien, Early Breast Cancer Trialists, EP Smith, F Mazzuca, FA Trémollieres, GK Ellis, HG Bone, HW Daniell, I Fogelman, I Sestak, J Morote, J Pfeilschifter, J Planas, Janet Brown, JD Wilson, JE Lester, JE Lester, JF Forbes, JL Mohler, JM Bruder, KB Emerton, KM Nicks, L Bošković, L Vehmanen, LC Hofbauer, LC Hofbauer, LH Klotz, LP Fried, M Bauer, M Datta, M Gnant, M Gnant, M Kalder, M Kalder, M Rabaglio, MD Michaelson, MG Oefelein, MM Agarwal, MR Smith, MR Smith, MR Smith, MR Smith, MR Smith, MR Smith, N Majithia, N Napoli, ND James, ND Wagner-Johnston, P Hadji, P Hadji, P Hadji, P Hadji, P Rodrigues, PD Miller, PE Goss, PE Goss, PL Nguyen, R Choo, R Coleman, R Coleman, R Eastell, R Eastell, R Soleimani, RA Adler, RE Coleman, RJ Segal, Robert Coleman, S Dhesy-Thind, S D’Oronzo, SL Greenspan, Stella D’Oronzo, SY Ying, T Kameda, T Liu, T Rana, T Saarto, TA Guise, TH Diamond, TJ Powles, V Carnevale, V Subbiah, VB Shahinian, W Vale, WJ Boyle   +109 more
core   +2 more sources

Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG‐1901 Study

Cancer Science, Volume 117, Issue 2, Page 501-510, February 2026.
The KYUCOG‐1901 prospective multicenter study evaluated radium‐223 in 93 Japanese patients with bone‐metastatic castration‐resistant prostate cancer. Ra‐223 was well tolerated, produced meaningful declines in ALP, and yielded a median overall survival of 23.0 months. Early initiation in patients with lower disease burden and integration with subsequent
Masaki Shiota, Shuichi Tatarano, Tomomi Kamba, Toshiyuki Kamoto, Tsukasa Igawa, Naoya Masumori, Hirotsugu Uemura, Kensuke Mitsunari, Takayuki Sumiyoshi, Hiroji Uemura, Katsuyoshi Higashijima, Shoji Tokunaga, Masatoshi Eto   +12 more
wiley   +1 more source

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience

Therapeutic Advances in Urology, 2017
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality.
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer   +3 more
doaj   +1 more source

Denosumab cessation [PDF]

Cleveland Clinic Journal of Medicine, 2020
openaire   +2 more sources

FRI0551 Use of glucocorticoid is the risk factor for inadequate response to the treatment of osteoporosis by denosumab [PDF]

, 2017
Kumi Orita, Tatsuya Koike
openalex   +1 more source

A Case of Denosumab-associated Hyperparathyroidism: Differential Diagnosis Challenge

, 2021
Emin Taşkıran, Sevnaz Şahin, Sumru Savaş, Fulden Saraç, Selahattin Akçiçek   +4 more
openalex   +1 more source

Denosumab-induced hypocalcemia post bariatric surgery—a severe and protracted course: a case report [PDF]

, 2023
Mohd Hazriq Awang, Sharifah Faradila Wan Muhamad Hatta, Aimi Fadilah Mohamad, Rohana Abdul Ghani   +3 more
openalex   +1 more source

Effect of metformin on inflammation and bone damage in a rat model of medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 134, Issue 1, February 2026.
Abstract This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v.
Liviane Maria Alves Rabelo, Mariana Vasconcelos Guimarães, Aurilene Gomes Cajado, José Vitor Mota Lemos, Felipe Domingos de Sousa, Nylane Maria Nunes Alencar, Vilma de Lima, Paulo Goberlânio de Barros Silva, Ana Paula Negreiros Nunes Alves, Deysi Viviana Tenazoa Wong, Roberto César Pereira Lima‐Júnior   +10 more
wiley   +1 more source

Denosumab-induced severe hypocalcemia in a patient with Crohn's disease [PDF]

, 2014
Osteoporosis occurs with increased prevalence in individuals with inflammatory bowel disease (IBD), and as such, these patients are at risk for osteoporosis-related fractures.
Katta, Natraj, Mulyala, Rajasekhar, Spiegel, Michelle, Tidwell, Tonya   +3 more
core  

PDG43 SAFETY EVALUATION OF ZOLEDRONIC ACID AND DENOSUMAB USING FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE 2012-2018 [PDF]

, 2019
Zizi Elsisi, Andrea Lin, J.J. Guo
openalex   +1 more source